Showing 4411-4420 of 8850 results for "".
- Crown Taps Shellie Hammock as EVP and General Counselhttps://practicaldermatology.com/news/crown-taps-shellie-hammock-as-evp-and-general-counsel/2461483/Shellie Hammock is Crown Laboratory’s new Executive Vice President and General Counsel and will hold a position on the Executive Leadership Team and Global Strategic Planning Team. This is a new position within Crown that will provide strategic legal oversight across al
- Leo Pharma's Adtralza Gets Nod or Adults with AD in Japanhttps://practicaldermatology.com/news/leo-pharmas-adtralza-gets-nod-or-adults-with-ad-in-japan/2461476/The Japan Ministry of Health, Labor and Welfare has granted approval for the manufacturing and marketing of LEO Pharma’s Adtralza (tralokinumab) subcutaneous injection for adults with atopic dermatitis, which has inadequately responded to conventional therapies. “Today&
- Hydrafacial, DOCTOR BABOR Collab for New Collagen HA Boosterhttps://practicaldermatology.com/news/hydrafacial-doctor-babor-collab-for-new-collagen-ha-booster/2461461/The Beauty Health Company’s Hydrafacial launched a new booster co-created with BABOR Skincare. The new DOCTOR BABOR Collagen HA booster is inspired by DOCTOR BABOR’s formulations and developed with the BABOR Laboratories in Germany. “Hydrafacial has cre
- American Hair Research Society to Host Hybrid Alopecia Areata Summit 12/10-11https://practicaldermatology.com/news/american-hair-research-society-to-host-hybrid-alopecia-areata-summit-1210-11/2461459/The Alopecia Areata Summit “New Pathways, New Treatments” organized by the American Hair Research Society will be held December 10-11 at the New York Academy of Medicine, 1216 5th Ave., New York, NY. The meeting is being co-Chaired by Angela M. Christiano, PhD, Columbia Univ
- Crown’s Patented Xycrobe Technology Supports a Healthy Skin Microbiomehttps://practicaldermatology.com/news/crowns-patented-xycrobe-technology-supports-a-healthy-skin-microbiome/2461440/Crown Aesthetics’ BIOJUVE regimen, which incorporates the patented Xycrobe technology, supports a healthy skin environment, promotes increased skin hydration, decreases redness, regulates sebum production and reduces the appearance of signs of aging such as fine lines and photodam
- FDA Clears the Accure Laser System for the Treatment of Mild to Severe Inflammatory Acne Vulgarishttps://practicaldermatology.com/news/fda-clears-the-accure-laser-system-for-the-treatment-of-mild-to-severe-inflammatory-acne-vulgaris/2461439/The FDA has cleared Accure Acne Inc's Accure Laser System to treat mild to severe inflammatory acne vulgaris. The Accure Laser System builds upon the unique selectivity of the 1726nm laser wavelength, adding proprietary technology to precisely control thermal gradient depth. This technology b
- Supergoop! Founder & CEO Named Ernst & Young LLP’s Entrepreneurs of the Year for 2022https://practicaldermatology.com/news/supergoop-founder-ceo-named-ernst-young-llps-entrepreneurs-of-the-year-for-2022/2461430/Holly Thaggard and Amanda Baldwin of Supergoop! are Ernst & Young LLP’s Entrepreneurs of the Year for 2022. The Entrepreneur of the Year program honors and elevates entrepreneurs who think big and act boldly to change our world for nearly four decades.
- Revance Shares Two Publications in The Aesthetic Surgery Journal That Advance Glabellar Line Injection Technique and Assessmenthttps://practicaldermatology.com/news/revance-shares-two-publications-in-the-aesthetic-surgery-journal-that-advance-glabellar-line-injection-technique-and-assessment/2461425/Two peer-reviewed articles in the Aesthetic Surgery Journal, the official journal of The Aesthetic Society, highlight the nuances of glabellar line injection technique and aim to improve patient outcomes, irrespective of the neuromodulator used. The
- Happy 30th Birthday NRS!https://practicaldermatology.com/news/happy-30th-birthday-nrs/2461410/The National Rosacea Society (NRS) is celebrating its 30th anniversary in 2022. The past three decades have seen tremendous progress toward fulfilling our mission of improving the lives of people with rosacea through awareness, education and support of medical research.
- EMA Accepts Filing of MAA for Almirall's Lebrikizumab in ADhttps://practicaldermatology.com/news/ema-accepts-filing-of-maa-for-almiralls-lebrikizumab-in-ad/2461408/The European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for Almirall’s lebrikizumab for the treatment of moderate to severe atopic dermatitis. Lebrikizumab is a novel, investigational, monoclonal antibod